The data published on Disclosure UK today shows that the industry invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018.
The ABPI’s consultation on the proposed 2021 Code of Practice is now open and we welcome your feedback.
The COVID-19 pandemic is an unprecedented situation that is constantly changing. To help you understand how the pharmaceutical industry is responding, we answer your questions.
We’re in regular contact, both with our members and the Government about any impact that the coronavirus could have on medicine supply in the UK.
This information is updated regularly, however it does not supersede advice or information provided by the relevant Government bodies and regulators.
The Government has confirmed that COVID-19 testing capacity will increase.
As part of the health community, the life sciences sector in the UK wants to play as big a role as possible in tackling COVD-19.
01 July 2020
The Government has published its R&D Roadmap with plans to cement the UK as the world’s leading research and science superpower.
30 June 2020
The data published on Disclosure UK today shows that the industry invested £381.2 million on R&D activities in the UK during 2019, up from £377.3million in 2018.
19 June 2020
The ABPI is launching a public consultation on the proposed 2021 ABPI Code of Practice for the pharmaceutical industry from today. The aim is to create a new look, more user-friendly ABPI Code of Practice.
18 June 2020
The Department of Health has announced that a scheme to kickstart the development of new antibiotics by offering to pay pharmaceutical companies upfront for their work will start this week.
18 June 2020
Before the coronavirus pandemic, this Thursday would have been the annual Chwarae Teg Womenspire Awards 2020 - celebrating the achievements of women from all backgrounds and stages in life or work across Wales.
25 May 2020
As Gavi marks its twentieth anniversary, a new report from the ABPI and IFPMA looks at the past successes of the Vaccines Alliance and what the future holds. Richard Torbett looks ahead to that commitment to protect future generations from infectious diseases.